These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

553 related articles for article (PubMed ID: 12642709)

  • 21. 18-Fluorodeoxyglucose-positron emission tomography in inflammatory breast cancer.
    Baslaim MM; Bakheet SM; Bakheet R; Ezzat A; El-Foudeh M; Tulbah A
    World J Surg; 2003 Oct; 27(10):1099-104. PubMed ID: 12917770
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Positron emission tomography with 11C-acetate and 18F-FDG in prostate cancer patients.
    Fricke E; Machtens S; Hofmann M; van den Hoff J; Bergh S; Brunkhorst T; Meyer GJ; Karstens JH; Knapp WH; Boerner AR
    Eur J Nucl Med Mol Imaging; 2003 Apr; 30(4):607-11. PubMed ID: 12589476
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of whole-body FDG-PET to bone scan for detection of bone metastases in patients with a new diagnosis of lung cancer.
    Cheran SK; Herndon JE; Patz EF
    Lung Cancer; 2004 Jun; 44(3):317-25. PubMed ID: 15140545
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Meta-analysis: comparison of F-18 fluorodeoxyglucose-positron emission tomography and bone scintigraphy in the detection of bone metastasis in patients with lung cancer.
    Chang MC; Chen JH; Liang JA; Lin CC; Yang KT; Cheng KY; Yeh JJ; Kao CH
    Acad Radiol; 2012 Mar; 19(3):349-57. PubMed ID: 22173321
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Positron emission tomography and bone metastases.
    Fogelman I; Cook G; Israel O; Van der Wall H
    Semin Nucl Med; 2005 Apr; 35(2):135-42. PubMed ID: 15765376
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Evaluation of bone scintigraphy and (18)F-FDG PET/CT in bone metastases of lung cancer patients].
    Portilla-Quattrociocchi H; Banzo I; Martínez-Rodríguez I; Quirce R; Jiménez-Bonilla J; de Arcocha Torres M; Medina-Quiroz P; del Castillo R; Rubio-Vassallo A; Carril JM
    Rev Esp Med Nucl; 2011; 30(1):2-7. PubMed ID: 21208693
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of FDG-PET/CT and bone scintigraphy for detection of bone metastases in breast cancer.
    Hahn S; Heusner T; Kümmel S; Köninger A; Nagarajah J; Müller S; Boy C; Forsting M; Bockisch A; Antoch G; Stahl A
    Acta Radiol; 2011 Nov; 52(9):1009-14. PubMed ID: 21969709
    [TBL] [Abstract][Full Text] [Related]  

  • 28. "One-stop-shop" staging: should we prefer FDG-PET/CT or MRI for the detection of bone metastases?
    Heusner T; Gölitz P; Hamami M; Eberhardt W; Esser S; Forsting M; Bockisch A; Antoch G
    Eur J Radiol; 2011 Jun; 78(3):430-5. PubMed ID: 19945240
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of 18F-FDG PET/CT in staging and restaging primary bone lymphoma.
    Liu Y
    Nucl Med Commun; 2017 Apr; 38(4):319-324. PubMed ID: 28225435
    [TBL] [Abstract][Full Text] [Related]  

  • 30. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging.
    Gallowitsch HJ; Kresnik E; Gasser J; Kumnig G; Igerc I; Mikosch P; Lind P
    Invest Radiol; 2003 May; 38(5):250-6. PubMed ID: 12750613
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Is methylene diphosphonate bone scan necessary for initial staging of Ewing sarcoma if 18F-FDG PET/CT is performed?
    Ulaner GA; Magnan H; Healey JH; Weber WA; Meyers PA
    AJR Am J Roentgenol; 2014 Apr; 202(4):859-67. PubMed ID: 24660717
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy comparison between (18)F-FDG PET/CT and bone scintigraphy in detecting bony metastases of non-small-cell lung cancer.
    Song JW; Oh YM; Shim TS; Kim WS; Ryu JS; Choi CM
    Lung Cancer; 2009 Sep; 65(3):333-8. PubMed ID: 19144446
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Accuracy of fluorodeoxyglucose-positron emission tomography for diagnosis of single bone metastasis: comparison with bone scintigraphy.
    Hur J; Yoon CS; Ryu YH; Yun MJ; Suh JS
    J Comput Assist Tomogr; 2007; 31(5):812-9. PubMed ID: 17895798
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diagnostic accuracy of bone metastases detection in cancer patients: comparison between bone scintigraphy and whole-body FDG-PET.
    Fujimoto R; Higashi T; Nakamoto Y; Hara T; Lyshchik A; Ishizu K; Kawashima H; Kawase S; Fujita T; Saga T; Togashi K
    Ann Nucl Med; 2006 Jul; 20(6):399-408. PubMed ID: 16922468
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical relevance of 18F-FDG-negative osteoblastic metastatic bone lesions noted on PET/CT in breast cancer patients.
    Al-Muqbel KM; Yaghan RJ; Al-Omari MH; Rousan LA; Dagher NM; Al Bashir S
    Nucl Med Commun; 2016 Jun; 37(6):593-601. PubMed ID: 26813990
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fusion of metabolic function and morphology: sequential [18F]fluorodeoxyglucose positron-emission tomography/computed tomography studies yield new insights into the natural history of bone metastases in breast cancer.
    Du Y; Cullum I; Illidge TM; Ell PJ
    J Clin Oncol; 2007 Aug; 25(23):3440-7. PubMed ID: 17592153
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Qualitative and quantitative comparison between images obtained with filtered back projection and iterative reconstruction in prostate cancer lesions of (18)F-FDG PET.
    Etchebehere EC; Macapinlac HA; Gonen M; Humm K; Yeung HW; Akhurst T; Scher HI; Larson SM
    Q J Nucl Med; 2002 Jun; 46(2):122-30. PubMed ID: 12114875
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?
    Casneuf V; Delrue L; Kelles A; Van Damme N; Van Huysse J; Berrevoet F; De Vos M; Duyck P; Peeters M
    Acta Gastroenterol Belg; 2007; 70(4):331-8. PubMed ID: 18330088
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [18 F-fluorodeoxyglucose positron emission tomography for characterization and initial staging of pancreatic tumors].
    Valinas R; Barrier A; Montravers F; Houry S; Talbot JN; Huguier M
    Gastroenterol Clin Biol; 2002 Oct; 26(10):888-92. PubMed ID: 12434099
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 18F-FDG PET in characterizing adrenal lesions detected on CT or MRI.
    Yun M; Kim W; Alnafisi N; Lacorte L; Jang S; Alavi A
    J Nucl Med; 2001 Dec; 42(12):1795-9. PubMed ID: 11752075
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.